[ad_1]
On September 26, the director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, said that monoclonal antibodies from recovered patients and other antiviral treatments could serve as a “bridge” to fight the coronavirus until the arrival of the vaccine. . . Therapeutic treatments such as Gilead Sciences Inc.’s remdesivir, steroid dexamethasone, and other antibody-based medical treatments are being investigated, Dr. Fauci said in an interview with the American Medical Association. The focus on treating early infection or preventing infection is the bridge to the vaccine, he said.
When the global case count reached 33,058,557, the Director of the National Institutes of Allergy and Infectious Diseases (NIAID) warned that those numbers had to be lowered, especially with the risk of flu cases during the winter. Vaccination against SARS-CoV-2 in the US could begin in November or December, Dr. Fauci said, as the US reaches 7 million confirmed COVID-19 cases. However, he warned that there might still be some time to restore normalcy before COVID. And even with vaccines, it will be at least the third quarter of 2021 before COVID-19 can be brought under control. At least 2 clinical trials of 30,000 volunteers are expected to conclude by the end of the year, the top U.S. infectious diseases official said in the live-streamed interview, adding that the trials could end sooner if interim results were overwhelming. .
Read: Peru extends the national state of emergency linked to the coronavirus until October 31
Read: 84 More Contract Coronavirus at UP’s Muzaffarnagar
700 million supply in the US
Fauci, speaking to WADA, said he had confidence in the independent members of the DSMB, who were not government officials, to set high standards without political influence or pressure. He added that more than 100 million doses of vaccine could be produced by up to 6 leading manufacturers, making for a supply of 700 million in the US by April 2021. A professor of medicine at the University of California in San Diego, Robert Schooley, also insisted that more attention should be paid to existing antiviral treatment without an effective and safe coronavirus vaccine on the horizon yet. The vaccine may not be 100 percent effective, he reiterated, adding that the efficacy of the oral antiviral drug should be considered in slowing the early onset of the disease.
Read: WHO says 2 million coronavirus deaths are ‘very likely’ even with vaccine
Read: Tiny airborne particles can pose a big coronavirus problem
(Image credit: AP)
[ad_2]
